Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

@article{Centanni2019ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors},
  author={Maddalena Centanni and D. Moes and I. Troc{\'o}niz and J. Ciccolini and J. G. V. van Hasselt},
  journal={Clinical Pharmacokinetics},
  year={2019},
  volume={58},
  pages={835 - 857}
}
Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in improving overall survival of several malignancies associated with poor outcomes; however, only 20–40% of patients will show long-lasting survival. Further clarification of factors related to treatment response can support improvements in clinical outcome and guide the development of novel immune checkpoint therapies. In this article, we have provided an overview of the pharmacokinetic (PK) aspects related to… Expand
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 123 REFERENCES
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
Management of immune-related adverse events and kinetics of response with ipilimumab.
...
1
2
3
4
5
...